JP2015524823A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524823A5
JP2015524823A5 JP2015525617A JP2015525617A JP2015524823A5 JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5 JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015524823 A5 JP2015524823 A5 JP 2015524823A5
Authority
JP
Japan
Prior art keywords
composition according
antithrombin
recombinant antithrombin
administered
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524823A (ja
JP6389172B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/053365 external-priority patent/WO2014022748A1/en
Publication of JP2015524823A publication Critical patent/JP2015524823A/ja
Publication of JP2015524823A5 publication Critical patent/JP2015524823A5/ja
Application granted granted Critical
Publication of JP6389172B2 publication Critical patent/JP6389172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525617A 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用 Expired - Fee Related JP6389172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
US61/679,345 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (3)

Publication Number Publication Date
JP2015524823A JP2015524823A (ja) 2015-08-27
JP2015524823A5 true JP2015524823A5 (cg-RX-API-DMAC10.html) 2016-09-23
JP6389172B2 JP6389172B2 (ja) 2018-09-12

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525617A Expired - Fee Related JP6389172B2 (ja) 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用

Country Status (13)

Country Link
US (1) US9511087B2 (cg-RX-API-DMAC10.html)
EP (1) EP2879697A4 (cg-RX-API-DMAC10.html)
JP (1) JP6389172B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150039201A (cg-RX-API-DMAC10.html)
CN (1) CN104884080A (cg-RX-API-DMAC10.html)
AR (1) AR091977A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013296240B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015002321A2 (cg-RX-API-DMAC10.html)
CA (1) CA2879763C (cg-RX-API-DMAC10.html)
IL (1) IL236776A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015001508A (cg-RX-API-DMAC10.html)
TW (1) TW201425332A (cg-RX-API-DMAC10.html)
WO (1) WO2014022748A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
CN104884080A (zh) 2012-08-03 2015-09-02 Lfb美国股份有限公司 抗凝血酶在体外膜式氧合中的用途
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6528699B1 (en) 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
AU2004271200A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
US20060292213A1 (en) 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
EP1913155A4 (en) 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
AU2012278836B2 (en) 2011-07-07 2016-03-10 Lfb Usa, Inc. Formulations that stabilize proteins
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
CN104884080A (zh) 2012-08-03 2015-09-02 Lfb美国股份有限公司 抗凝血酶在体外膜式氧合中的用途

Similar Documents

Publication Publication Date Title
JP2019524690A5 (cg-RX-API-DMAC10.html)
NZ631155A (en) Combination of two antivirals for treating hepatitis c
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
ME02662B (me) Niskofrekventna terapija glatiramer acetatom
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
JP2013509429A5 (cg-RX-API-DMAC10.html)
JP2015502389A5 (cg-RX-API-DMAC10.html)
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
FI3978074T3 (fi) Terlipressiini tyypin 1 hepatorenaalisen syndrooman hoitamiseksi
HRP20200009T1 (hr) Angiotenzin ii u kombinaciji za liječenje hipotenzije
FI3630164T3 (fi) Dulaglutidi kroonisen munuaissairauden hoitoon
JP2015516419A5 (cg-RX-API-DMAC10.html)
HK1255481A1 (zh) 用於治疗hcv的方法
CN104884080A (zh) 抗凝血酶在体外膜式氧合中的用途
CA2525202A1 (en) Use of alpha interferon, ribavirin, dsrna and neuraminidase inhibitors to treat avian influenza
JP2012526099A5 (cg-RX-API-DMAC10.html)
CN102488697A (zh) 一种寡聚甘露糖醛酸在制备抗甲型h1n1流感病毒药物中的应用
FR2961695B1 (fr) Utilisation de composes dans le traitement ou la prevention de troubles cutanes
JP2019507134A5 (cg-RX-API-DMAC10.html)
JP2017508455A5 (cg-RX-API-DMAC10.html)
JP2010538054A5 (cg-RX-API-DMAC10.html)
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
JP2016510040A5 (cg-RX-API-DMAC10.html)
NZ708511A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
HRP20241358T1 (hr) Liječenje hipotenzije sa sepsom ili septičkim šokom